J. Lipid Res.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

A more recent version of this article appeared on April 1, 2007

Papers In Press, published online ahead of print January 26, 2007
J. Lipid Res., doi:10.1194/jlr.P600014-JLR200
This Article
Right arrow Full Text (Accepted Manuscript)
Right arrow All Versions of this Article:
P600014-JLR200v1
48/4/952    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bisoendial, R. J.
Right arrow Articles by Stroes, E. S.G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bisoendial, R. J.
Right arrow Articles by Stroes, E. S.G.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Submitted on October 24, 2006
Revised on December 26, 2006
Accepted on January 26, 2007

Effects of CRP-infusion on endothelial function and coagulation in normo- and hypercholesterolemic subjects

Radjesh J. Bisoendial, John J. P. Kastelein, Stephan L. M. Peters, Johannes H. M. Levels, Rakesh Birjmohun, Joris I. Rotmans, Daniel Hartman, Joost C. M. Meijers, Marcel Levi, and Erik S.G. Stroes

vascular medicine, Academic Medical Center, Amsterdam 1105 AZ

Corresponding Author: r.j.bisoendial{at}amc.uva.nl

C-reactive protein (CRP) has been suggested to exert direct adverse effects on the vasculature in experimental setups, including endothelial dysfunction and pro-inflammatory changes. Here, we assessed the consequences of 1·25 mg/kg highly purified recombinant human (rh)CRP, administered as a intravenous bolus, in six patients with familial hypercholesterolemia (FH) and six normocholesterolemic subjects. Endothelium-dependent and –independent vasoreactivity to serotonin and nitroprusside, respectively, were assessed using venous occlusion plethysmography before and after CRP-infusion. For biochemical analyses, blood was drawn at different time-points. At baseline, FH-patients showed blunted endothelium-dependent vasodilation (max 89·2±30·0% versus 117·7±13·1% in normolipidemic subjects; p=0·037). Procoagulant activity was also higher in FH-patients, illustrated by elevated prothrombin fragment 1+2 (F1+2) levels (p=0·030) and plasminogen activator inhibitor type-1 (PAI-1) activity (p=0·016). Upon CRP-challenge, endothelium-dependent vasodilator capacity further deteriorated in FH-patients (p=0·029), whereas no change in vascular reactivity was observed in normolipidemic subjects. Additionally, coagulation activation was augmented in FH-patients compared to normolipidemic subjects (p=0·009 for F1+2 levels; p=0·018 and p=0·003 for PAI-1 antigen and activity, respectively). No difference in inflammatory responses was observed between groups. In hypercholesterolemic patients, CRP aggravates endothelial dysfunction and also evoke augmented procoagulant responses. These findings suggest that particularly in hypercholesterolemia, CRP-lowering strategies should be considered in addition to LDL-reduction.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 All ASBMB Journals   Journal of Biological Chemistry 
 Molecular and Cellular Proteomics   ASBMB Today 
Copyright © 2007 by the American Society for Biochemistry and Molecular Biology.